Literature DB >> 12022340

Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children.

An D Billiau, Freddy Cornillie, Carine Wouters.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12022340

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  5 in total

1.  [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

Review 2.  [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 3.  Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

Review 4.  Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.

Authors:  Songkiat Chantarogh; Soamarat Vilaiyuk; Thipwimol Tim-Aroon; Suchin Worawichawong
Journal:  BMC Nephrol       Date:  2017-05-12       Impact factor: 2.388

5.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.